Global Cell and Gene Therapy Market Share, Size, Drivers, Opportunitues: By Type: Cell Therapy Types, Gene Therapy Types; By Indications: Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases, Dermatology, Endocrine, Metabolic, Genetic, Others; By Product Type; By End User; Regional Analysis; Supplier Landscape; 2023-2031

Global Cell and Gene Therapy Market Outlook

The global cell and gene therapy market size attained a value of USD 17.4 billion in 2022. The market is expected to rise at a CAGR of 23.17% during the forecast period of 2023-2031 to attain a value of USD 113.64 billion by 2031, driven by the rising prevalence of chronic diseases.

 

cell and gene therapy cgt market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Cell and Gene Therapy: A Brighter Future Outlook

The global cell and gene therapy market is a comparatively new integration of technology and genomics, that has been enthralled by substantial new developments in the healthcare industry. Cell and gene therapy are the two conjoining therapies incorporated as a single therapy for efficient and effective treatment. The emerging new cell and gene therapies are sure to burgeon the biotechnological and biopharmaceutical industry in the coming years.

 

Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In cell therapy, cells are modified outside the body, that is, in ex-vivo conditions and then injected into the patient. On the other hand, gene therapy works by incorporating, deactivating, or displacing the genes into cells which can occur both inside (in vivo) and outside (ex vivo) of the body.

 

In the healthcare sector, some of the major treatments and curative remedies are developed using cell and gene modifications. Cell and gene therapy works by modifying the genes in particular cells and injecting them into the body. The essential resemblance between cell and gene therapy is the ability to mitigate the underlying cause of genetic disorders. There are enormous cell and gene therapies based on the origin or destination as per the treatment requirements.

 

Based on the genetic manipulation and source, cell and gene therapies are classified into two categories- ex vivo and in vivo. The ex vivo ones are further categorised into allogenic and autologous.

 

Autologous therapies require raw materials to be referenced and returned to the same subject. At the same time, allogeneic therapies deliver it through material from any optimum donor. Cell therapies utilise genetically modified (for example CAR-T therapy) and non-genetically modified cells (Beta cells T1D) as medicines. In contrast, gene therapies use viral (lipid/polymer based) and non-viral (mRNA) vectors as medicines.

 

Researchers are working on several new cell and gene therapies in the new disease sectors, which will help in improving the overall market outlook.

 

Market Segmentations

According to the cell and gene therapy market research report, the market can be categorised into the following segments:

 

cell and gene therapy cgt market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Breakup by Type

  • Cell Therapy Types
    • Autologous Cell Therapy
    • Autogenic Cell Therapy
    • Ex-vivo Cell Therapy
    • In-vivo Cell Therapy
  • Gene Therapy Types
    • Somatic Cell Gene Therapy
    • Germline Gene Therapy
    • Ex-vivo Gene Therapy
    • In-vivo Gene Therapy

Market Breakup by Indications

  • Oncology
  • Cardiology
  • CNS
  • Musculoskeletal
  • Infectious Diseases
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology and Inflammation
  • Ophthalmology
  • Haematology
  • Gastroenterology
  • Others

 

Market Breakup by Product Type

  • Yescarta
  • Provenge
  • Luxtura
  • Kymriah
  • Imlygic
  • Gintuit
  • MACI
  • Laviv
  • Gendicine
  • Oncorine
  • Neovasculgen
  • Strimvelis
  • Invossa
  • Zolgenesma
  • Tecartus
  • Lisocel
  • Zyntelego
  • Others

 

Cell and Gene Therapy Market Breakup by End User

  • Hospitals
  • Ambulatory Surgical Centres
  • Wound Care Centres
  • Cancer Care Centres
  • Others

 

Market Breakup by Region

  • North America
    • United States of America
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others

 

cell and gene therapy cgt market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Cell and Gene Therapy Market Scenario

The emerging cell and gene therapies seem promising in commercial aspects. Key market leaders will be the gene therapy companies that will provide fast and effective treatment for debilitating diseases. Gene therapies developed by small, medium, and big biotech and pharmaceutical companies also tend to attract the attention of investors. According to Food and Drug Administration’s anticipation, by 2025, 10 to 20 new cell and gene therapies can be approved.

 

According to the research surveys, publicly traded cell and gene therapies also witnessed a 70% increase in stocks compared to the previous year. This demonstrates the substantial growth of the cell and gene therapy market in the upcoming years.

 

The increase in the prevalence of chronic disorders, like cancer, is responsible for driving the growth of this market. The increased expenditure in the R&D sector and enhanced government support are also expected to boost the cell and gene therapy market development during the forecast period.

 

Advanced technologies and better healthcare infrastructure facilities are the additional factors helping in the development of this market.

 

Based on regions, North America accounts for a significant share of the global market due to the growth of the market in the United States. The United States of America has witnessed a substantial increase in biopharmaceutical companies performing clinical trials in cell and gene therapy. Thus, the United States hold a significant share in the global cell and gene therapy market.

 

The growth of the market in the United States can be attributed to the higher presence of the key players in the region. It was found that more than 1000 companies worldwide are working on cell and gene therapy, out of which more than 500 companies are based in the United States.

 

Across the globe, around 250 are from Europe, about 150 are in the Asian region and the rest are found in other regions like Oceania, New Zealand, Australia, and Africa.

 

Therapeutic Landscape

Over the last decade, cell and gene therapy have accelerated and resulted in multiple effective treatments for various indications. These novel therapies and strategies have grabbed the attention of the entire biotech and pharma industry and are visible as future hallmarks of the global cell and gene therapy market. The field of cell and gene therapy is still young compared to other modalities.

 

A collaborative industry effort has focused on applying chimeric anti-receptor T-cells for oncology indications. The incorporation of cell and gene therapy in hematopoietic stem cells has paved the pathway for new therapeutic strategies, including haematological, neurological, and ocular symptoms.

 

Emerging Regenerative Medicine and Gene Alteration Technologies

Novartis Pharmaceuticals were doing clinical trials to monitor the long-term safety of CAR-T patients. The purpose of this trial was to monitor all patients who were incorporated with CAR-T therapies for fifteen years following their last CAR-T infusion.

 

Researchers did clinical trials for the first FDA-approved in vivo therapy to treat retinal dystrophies caused by the modified RPE65 gene. This therapy is incorporated with the help of the adeno-associated vector, which will target the retinal cells and insert the healthy genes into the patient’s eye.

 

Cell and gene therapy for Haemophilia is also entering the last stage of the clinical trials. There are already ten ongoing trials for Haemophilia A and six for Haemophilia B. In this therapy, a single injection of adeno-associated virus (AAV) is engineered in the liver to produce the essential clotting factor for the rest of the patient’s life.

 

Another set of clinical trials utilising cell and gene alteration is under process in the United States to treat degenerative retinal diseases. In this therapy, an intraocular injection pass on the genes encoding for MCO protein into the retinal cells. These trials are also in the phase II stage.

 

Implementing cell and gene technology in healthcare has already provided enormous benefits to human health. Researchers’ tremendous efforts have anticipated a rapid increase in the approvals for cell and gene therapies. A rapid rise in authorisations for gene therapies is also expected. Careful planning and research are done to overcome all the hurdles and hindrances and for the vast development.

 

Several ongoing clinical trials are emerging as a driving factor for cell and gene therapy market growth and development.

 

Competitive Landscape

The report gives an in-depth therapy and the key players involved in the cell and gene therapy market, sponsors manufacturing the therapies, and putting them through trials to get FDA approvals. The companies included in the market are as follows:

 

  • Amgen, Inc.
  • Bluebird Bio, Inc.
  • Castle Creek Pharmaceutical Holdings
  • Kite Pharma, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Vericel Corporation
  • Vericel Corporation
  • Human Stem Cells Institute
  • Kolon Tissuegene Inc.
  • Organogenesis Holdings Inc.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2018-2022
Forecast Period 2023-2028
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Type
  • Indications
  • Product Type
  • End User
  • Region
Breakup by Type
  • Cell Therapy Types
  • Gene Therapy Types
Breakup by Indications
  • Oncology
  • Cardiology
  • CNS
  • Musculoskeletal
  • Infectious Diseases
  • Dermatology
  • Endocrine, Metabolic, Genetic
  • Immunology and Inflammation
  • Ophthalmology
  • Haematology
  • Gastroenterology
  • Others
Breakup by Product Type
  • Yescarta
  • Provenge
  • Luxtura
  • Kymriah
  • Imlygic
  • Gintuit
  • MACI
  • Laviv
  • Gendicine
  • Oncorine
  • Neovasculgen
  • Strimvelis
  • Invossa
  • Zolgenesma
  • Tecartus
  • Lisocel
  • Zyntelego
  • Others
Breakup by End User
  • Hospitals
  • Ambulatory Surgical Centres
  • Wound Care Centres
  • Cancer Care Centres
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter's Five Forces Model
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Financial Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Amgen, Inc.
  • Bluebird Bio, Inc.
  • Castle Creek Pharmaceutical Holdings
  • Kite Pharma, Inc.
  • Novartis AG
  • Orchard Therapeutics plc.
  • Pfizer, Inc.
  • Spark Therapeutics, Inc.
  • Vericel Corporation
  • Human Stem Cells Institute
  • Kolon Tissuegene Inc.
  • Organogenesis Holdings Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions 
    1.3    Report Coverage – Key Segmentation and Scope  
    1.4    Research Methodology
2    Executive Summary
3    Global Cell and Gene Therapy Market Overview

    3.1    Global Cell and Gene Therapy Market Historical Value (2016-2022) 
    3.2    Global Cell and Gene Therapy Market Forecast Value (2023-2031)
4    Global Cell and Gene Therapy Market Landscape
    4.1    Global Cell and Gene Therapy Developers Landscape
        4.1.1    Analysis by Year of Establishment
        4.1.2    Analysis by Company Size
        4.1.3    Analysis by Region
    4.2    Global Cell and Gene Therapy Product Landscape
        4.2.1    Analysis by Type
        4.2.2    Analysis by Indications
        4.2.3    Analysis by End Users
5    Global Cell and Gene Therapy Market Dynamics
    5.1    Market Drivers and Constraints
    5.2    SWOT Analysis
    5.3    Porter’s Five Forces Model 
    5.4    Key Demand Indicators
    5.5    Key Price Indicators
    5.6    Industry Events, Initiatives, and Trends 
    5.7    Value Chain Analysis
6    Global Cell and Gene Therapy Market Segmentation
    6.1    Global Cell and Gene Therapy Market by Type
        6.1.1    Market Overview
        6.1.2    Cell Therapy Types
            6.1.2.1    Autologous Cell Therapy
            6.1.2.2    Autogenic Cell Therapy
            6.1.2.3    Ex-vivo Cell Therapy
            6.1.2.4    In-vivo Cell Therapy
        6.1.3    Gene Therapy Types
            6.1.3.1    Somatic Cell Gene Therapy
            6.1.3.2    Germline Gene Therapy
            6.1.3.3    Ex-vivo Gene Therapy
            6.1.3.4    In-vivo Gene Therapy
    6.2    Global Cell and Gene Therapy Market by Indications
        6.2.1    Market Overview
        6.2.2    Oncology
        6.2.3    Cardiology
        6.2.4    CNS
        6.2.5    Musculoskeletal
        6.2.6    Infectious Diseases
        6.2.7    Dermatology
        6.2.8    Endocrine, Metabolic, Genetic
        6.2.9    Immunology and Inflammation
        6.2.10    Ophthalmology
        6.2.11    Haematology
        6.2.12    Gastroenterology
        6.2.13    Others
    6.3    Global Cell and Gene Therapy Market by Product Type
        6.3.1    Market Overview
        6.3.2     Yescarta 
        6.3.3    Provenge 
        6.3.4    Luxtura 
        6.3.5    Kymriah 
        6.3.6    Imlygic 
        6.3.7    Gintuit 
        6.3.8    MACI 
        6.3.9    Laviv 
        6.3.10    Gendicine 
        6.3.11    Oncorine 
        6.3.12    Neovasculgen 
        6.3.13    Strimvelis 
        6.3.14    Invossa 
        6.3.15    Zolgenesma 
        6.3.16    Tecartus 
        6.3.17    Lisocel 
        6.3.18    Zyntelego 
        6.3.19    Others
    6.4    Global Cell and Gene Therapy Market by End User
        6.4.1    Market Overview
        6.4.2    Hospitals
        6.4.3    Ambulatory Surgical Centres
        6.4.4    Wound Care Centres
        6.4.5    Cancer Care Centres
        6.4.6    Others
    6.5    Global Cell and Gene Therapy Market by Region
        6.5.1    Market Overview
        6.5.2    North America 
        6.5.3    Europe
        6.5.4    Asia Pacific
        6.5.5    Latin America
        6.5.6    Middle East and Africa
7    North America Cell and Gene Therapy Market
    7.1    Market Share by Country
    7.2    United States of America
    7.3    Canada
8    Europe Cell and Gene Therapy Market
    8.1    Market Share by Country
    8.2    United Kingdom
    8.3    Germany
    8.4    France
    8.5    Italy
    8.6    Others
9    Asia Pacific Cell and Gene Therapy Market
    9.1    Market Share by Country
    9.2    China
    9.3    Japan
    9.4    India
    9.5    ASEAN
    9.6    Australia
    9.7    Others
10    Latin America Cell and Gene Therapy Market
    10.1    Market Share by Country
    10.2    Brazil
    10.3    Argentina
    10.4    Mexico
    10.5    Others
11    Middle East and Africa Cell and Gene Therapy Market
    11.1    Market Share by Country
    11.2    Saudi Arabia
    11.3    United Arab Emirates
    11.4    Nigeria
    11.5    South Africa
    11.6    Others
12    Patent Analysis
    12.1    Analysis by Type of Patent
    12.2    Analysis by Publication year
    12.3    Analysis by Issuing Authority
    12.4    Analysis by Patent Age
    12.5    Analysis by CPC Analysis
    12.6    Analysis by Patent Valuation 
    12.7    Analysis by Key Players
13    Grants Analysis
    13.1    Analysis by year
    13.2    Analysis by Amount Awarded
    13.3    Analysis by Issuing Authority
    13.4    Analysis by Grant Application
    13.5    Analysis by Funding Institute
    13.6    Analysis by NIH Departments
    13.7    Analysis by Recipient Organization 
14    Funding Analysis
    14.1    Analysis by Funding Instances
    14.2    Analysis by Type of Funding
    14.3    Analysis by Funding Amount
    14.4    Analysis by Leading Players
    14.5    Analysis by Leading Investors
    14.6    Analysis by Geography
15    Partnership and Collaborations Analysis
    15.1    Analysis by Partnership Instances
    15.2    Analysis by Type of Partnership
    15.3    Analysis by Leading Players
    15.4    Analysis by Geography
16    Regulatory Framework
    16.1    Regulatory Overview
        16.1.1    US FDA
        16.1.2    EU EMA
        16.1.3    INDIA CDSCO
        16.1.4    JAPAN PMDA
        16.1.5    Others
17    Supplier Landscape
    17.1    Amgen, Inc.
        17.1.1    Financial Analysis
        17.1.2    Financial Portfolio
        17.1.3    Demographic Reach and Achievements
        17.1.4    Mergers and Acquisitions
        17.1.5    Certifications
    17.2    Bluebird Bio, Inc.
        17.2.1    Financial Analysis
        17.2.2    Financial Portfolio
        17.2.3    Demographic Reach and Achievements
        17.2.4    Mergers and Acquisitions
        17.2.5    Certifications
    17.3    Castle Creek Pharmaceutical Holdings
        17.3.1    Financial Analysis
        17.3.2    Financial Portfolio
        17.3.3    Demographic Reach and Achievements
        17.3.4    Mergers and Acquisitions
        17.3.5    Certifications
    17.4    Kite Pharma, Inc.
        17.4.1    Financial Analysis
        17.4.2    Financial Portfolio
        17.4.3    Demographic Reach and Achievements
        17.4.4    Mergers and Acquisitions
        17.4.5    Certifications
    17.5    Novartis AG
        17.5.1    Financial Analysis
        17.5.2    Financial Portfolio
        17.5.3    Demographic Reach and Achievements
        17.5.4    Mergers and Acquisitions
        17.5.5    Certifications
    17.6    Orchard Therapeutics plc.
        17.6.1    Financial Analysis
        17.6.2    Financial Portfolio
        17.6.3    Demographic Reach and Achievements
        17.6.4    Mergers and Acquisitions
        17.6.5    Certifications
    17.7    Pfizer, Inc.
        17.7.1    Financial Analysis
        17.7.2    Financial Portfolio
        17.7.3    Demographic Reach and Achievements
        17.7.4    Mergers and Acquisitions
        17.7.5    Certifications
    17.8    Spark Therapeutics, Inc.
        17.8.1    Financial Analysis
        17.8.2    Financial Portfolio
        17.8.3    Demographic Reach and Achievements
        17.8.4    Mergers and Acquisitions
        17.8.5    Certifications
    17.9    Vericel Corporation
        17.9.1    Financial Analysis
        17.9.2    Financial Portfolio
        17.9.3    Demographic Reach and Achievements
        17.9.4    Mergers and Acquisitions
        17.9.5    Certifications
    17.10     Human Stem Cells Institute
        17.10.1    Financial Analysis
        17.10.2    Financial Portfolio
        17.10.3    Demographic Reach and Achievements
        17.10.4    Mergers and Acquisitions
        17.10.5    Certifications
    17.11    Kolon Tissuegene Inc.
        17.11.1    Financial Analysis
        17.11.2    Financial Portfolio
        17.11.3    Demographic Reach and Achievements
        17.11.4    Mergers and Acquisitions
        17.11.5    Certifications
    17.12    Organogenesis Holdings Inc.
        17.12.1    Financial Analysis
        17.12.2    Financial Portfolio
        17.12.3    Demographic Reach and Achievements
        17.12.4    Mergers and Acquisitions
        17.12.5    Certifications
18    Global Cell and Gene Therapy Market - Distribution Model (Additional Insight)
    18.1    Overview 
    18.2    Potential Distributors 
    18.3    Key Parameters for Distribution Partner Assessment 
19    Key Opinion Leaders (KOL) Insights (Additional Insight)
20    Company Competitiveness Analysis (Additional Insight)

    20.1    Very Small Companies
    20.2    Small Companies
    20.3    Mid-Sized Companies
    20.4    Large Companies
    20.5    Very Large Companies
21    Payment Methods (Additional Insight)
    21.1    Government Funded
    21.2    Private Insurance
    21.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The market attained a value of USD 17.4 billion in 2022, driven by the rising technological advancements.

The market is expected to rise at a CAGR of 23.17% during the forecast period of 2023-2031 to attain a value of USD 113.64 billion by 2031, driven by the rising prevalence of chronic diseases.

The types of cell therapy include autologous cell therapy, autogenic cell therapy, ex-vivo cell therapy, and in-vivo cell therapy. gene therapy can be divided into somatic cell gene therapy, germline gene therapy, ex-vivo gene therapy, and in-vivo gene therapy.

The segmentations based on indication include oncology, cardiology, CNS, musculoskeletal, infectious diseases, dermatology, endocrine, metabolic, genetic, immunology and inflammation, ophthalmology, haematology, and gastroenterology, among others.

The product types in the market include Yescarta, Provenge, Luxtura, Kymriah, Imlygic, Gintuit, MACI, Laviv, Gendicine, Oncorine, Neovasculgen, Strimvelis, Invossa, Zolgenesma, Tecartus, Lisocel, and Zyntelego, among Others.

The end-users in the market include hospitals, ambulatory surgical centres, wound care centres, and cancer care centres, among others.

The regions involved in the market are North America, Middle East and Africa, Latin America, Asia Pacific, and Europe.

Cell therapy works on the principle of alteration, implantation, or restoration of cells or by extrapolating cells to carry the treatment through the body. In contrast, gene therapy works by incorporating, deactivating, or displacing the genes into cells which can occur both inside (in vivo) and outside (ex vivo) of the body.

The key companies involved in this market are Amgen, Inc., Bluebird Bio, Inc., Castle Creek Pharmaceutical Holdings, Kite Pharma, Inc., Novartis AG, Orchard Therapeutics plc., Pfizer, Inc., Spark Therapeutics, Inc., Vericel Corporation, Vericel Corporation, Human Stem Cells Institute, Kolon Tissuegene Inc., and Organogenesis Holdings Inc., among others.

Purchase Full Report

Mini Report

$3499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$5999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$7999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$9999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER